Repeatability of AI-quantified incidental findings on lung cancer screening CT scans in the NELSON trial - Takeaways - MDSpire

Repeatability of AI-quantified incidental findings on lung cancer screening CT scans in the NELSON trial

  • By

  • Stijn Bunk

  • Thijs Bruins Slot

  • Edwin Bennink

  • Grigory Sidorenkov

  • Nils van der Velden

  • Niels Schurink

  • Félix Lades

  • Markus Sebald

  • Marjolein A. Heuvelmans

  • Hester A. Gietema

  • Joachim G. Aerts

  • Geertruida H. de Bock

  • Cornelia Schaefer-Prokop

  • Pim A. de Jong

  • Rozemarijn Vliegenthart

  • Firdaus A. A. Mohamed Hoesein

  • June 17, 2026

  • 0 min

Share

  • 1

    Lung cancer screening with low-dose CT has reduced mortality but increases radiologists' workload due to incidental findings.

  • 2

    AI methods can automate the measurement of incidental findings, potentially reducing radiologists' workload and interpretive errors.

  • 3

    The study aims to evaluate the repeatability and agreement of AI measurements of incidental findings in lung cancer screening.

  • 4

    Data for the analysis were obtained from the NELSON trial, involving participants aged 50-75 with significant smoking history.

  • 5

    Measurements included aortic diameters, coronary artery calcium volume, vertebral body metrics, and emphysema quantification.

Original Source(s)

Repeatability of AI-quantified incidental findings on lung cancer screening CT scans in the NELSON trial

  • by Stijn Bunk, Thijs Bruins Slot, Edwin Bennink, Grigory Sidorenkov, Nils van der Velden, Niels Schurink, Félix Lades, Markus Sebald, Marjolein A. Heuvelmans, Hester A. Gietema, Joachim G. Aerts, Geertruida H. de Bock, Cornelia Schaefer-Prokop, Pim A. de Jong, Rozemarijn Vliegenthart, Firdaus A. A. Mohamed Hoesein

  • June 17, 2026

Related Content

StructSAM: structure-aware prompt adaptation for robust lung cancer lesion segmentation in CT

Advanced breath analysis through hierarchical deep convolutional neural network for multi-cancer screening

Single and multi-site CT-based radiogenomics analysis of metastatic lung adenocarcinoma and correlations with outcome